Zobrazeno 1 - 10
of 459
pro vyhledávání: '"MET exon 14 skipping"'
Autor:
Rongzhen Li, Xiaoyan Liu, Yan Xu, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 15, Iss 32, Pp 2339-2343 (2024)
Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping
Externí odkaz:
https://doaj.org/article/99ed271fb2f4452da56c2df66dccf708
Publikováno v:
Cancer Management and Research, Vol Volume 15, Pp 1233-1243 (2023)
Madison Fraser,1 Nagashree Seetharamu,2 Matthew Diamond,2 Chung-Shien Lee2,3 1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, USA; 2Division of Medical Oncology and Hematology, Northwell Health Ca
Externí odkaz:
https://doaj.org/article/4b2b439e748a42a199bd533c45e0c3af
Autor:
Tejas Patil, MD, Alyse Staley, MS, Yunan Nie, MD, Mandy Sakamoto, MD, Margaret Stalker, MD, James M. Jurica, MD, MBA, Kenna Koehler, BA, Amanda Cass, PharmD, Halle Kuykendall, BA, Emily Schmitt, MS, Emma Filar, BA, Evelina Reventaite, MS, Kurt D. Davies, PhD, Hala Nijmeh, PhD, Mary Haag, PhD, Benjamin A. Yoder, PharmD, Paul A. Bunn, MD, Erin L. Schenk, MD, PhD, Dara L. Aisner, MD, PhD, Wade T. Iams, MD, Melina E. Marmarelis, MD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100637- (2024)
Introduction: Acquired MET gene amplification, MET exon 14 skip mutations, or MET fusions can emerge as resistance mechanisms to tyrosine kinase inhibitors (TKIs) in patients with lung cancer. The efficacy and safety of combining MET TKIs (such as cr
Externí odkaz:
https://doaj.org/article/63d7bcf67c604305b7273bb565a9b37b
Publikováno v:
Chinese Journal of Lung Cancer, Vol 26, Iss 6, Pp 416-428 (2023)
The mesenchymal-epithelial transition factor (MET) exon 14 skipping mutation is mainly caused by the loss of c-Cbl tyrosine binding site. This mutation could result in a decrease in the degradation rate of proteasome-mediated MET proteins, trigger co
Externí odkaz:
https://doaj.org/article/6f2d31754eff4623abdd8d60636387b8
Publikováno v:
Respirology Case Reports, Vol 12, Iss 1, Pp n/a-n/a (2024)
Abstract Skeletal muscle metastasis of lung cancer is rare. However, clinicians should be aware that tumour‐induced nerve compression symptoms may develop.
Externí odkaz:
https://doaj.org/article/6c28431c96ff47c088443c6f6847cf3b
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e22515- (2023)
Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGF
Externí odkaz:
https://doaj.org/article/d031b2eaa3d244ce94ceeb5d6b22e885
Autor:
Sally C.M. Lau, MD, MPH, Kirstin Perdrizet, MD, Andrea S. Fung, MD, PhD, Danilo Giffoni M.M. Mata, MD, Jessica Weiss, PhD, Nick Holzapfel, MD, Geoffrey Liu, MD, Penelope A. Bradbury, MD, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc, Harriet Feilotter, MD, Brandon Sheffield, MD, David Hwang, MD, Ming Sound Tsao, MD, Susanna Cheng, MD, Parneet Cheema, MD, Natasha B. Leighl, MD, MMSc
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100562- (2023)
Introduction: NSCLC with MET exon 14 skipping mutation (METex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatm
Externí odkaz:
https://doaj.org/article/1c185004b807431a8e7cb5c371cc5890
Autor:
Satoshi Ikeo, Naoaki Yasuda, Yuki Sakai, Yasuyuki Hayashi, Akihiko Sokai, Toshiyuki Iwata, Takashi Nishimura
Publikováno v:
Thoracic Cancer, Vol 14, Iss 10, Pp 958-960 (2023)
Abstract Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET‐TKIs) have been approved for the treatment of non‐small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opaci
Externí odkaz:
https://doaj.org/article/e3ad42673b4f411f9daa85ca73927f31
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.